Docoh
Loading...

BDX Becton, Dickinson And

BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 65,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care.

Company profile

Ticker
BDX, BDXA, BDXB
Exchange
Website
CEO
Thomas Polen
Employees
Incorporated
Location
Fiscal year end
SEC CIK
IRS number
220760120

BDX stock data

(
)

Calendar

6 May 21
4 Aug 21
30 Sep 21
Quarter (USD)
Mar 21 Dec 20 Sep 20 Jun 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Sep 20 Sep 19 Sep 18 Sep 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
28 May 21 James C Lim Common Stock Sell Dispose S Yes No 241.68 3,429 828.72K 801
27 May 21 Fraser Claire Common Stock Sell Dispose S No No 241.36 390 94.13K 20,607
3 May 21 Jones Christopher Ian Montague Rights to Common Stock Under 1996 Directors Deferral Plan Common Stock Grant Aquire A No No 253.39 107 27.11K 7,823
2 Mar 21 Antoine C Ezell Common Stock Payment of exercise Dispose F No No 0 505 0 4,636
1 Mar 21 Thomas J Spoerel Common Stock Grant Aquire A No No 0 302 0 1,551

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

81.7% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 1469 1493 -1.6%
Opened positions 123 206 -40.3%
Closed positions 147 112 +31.3%
Increased positions 592 566 +4.6%
Reduced positions 517 517
13F shares
Current Prev Q Change
Total value 57.75B 59.83B -3.5%
Total shares 237.71M 239.04M -0.6%
Total puts 687.34K 1.08M -36.4%
Total calls 813.68K 1.01M -19.5%
Total put/call ratio 0.8 1.1 -21.1%
Largest owners
Shares Value Change
Vanguard 24.3M $5.91B -0.3%
BLK Blackrock 22.06M $5.36B -0.8%
Wellington Management 13.94M $3.39B +3.6%
STT State Street 11.95M $2.91B -0.8%
TROW T. Rowe Price 10.33M $2.51B -11.3%
MS Morgan Stanley 7.85M $1.91B +0.1%
Massachusetts Financial Services 4.44M $1.08B +0.3%
Geode Capital Management 4.34M $1.05B +4.5%
Generation Investment Management 3.84M $932.65M -0.3%
FSZ Fiera Capital 3.82M $929.42M -3.2%
Largest transactions
Shares Bought/sold Change
Longview Partners 3.33M +3.33M NEW
Norges Bank 0 -2.71M EXIT
FMR 2.6M -2.25M -46.4%
TROW T. Rowe Price 10.33M -1.31M -11.3%
First Eagle Investment Management 1.29M +1.04M +410.0%
AMP Ameriprise Financial 536.24K -830.08K -60.8%
Ninety One UK 2.33M +651.51K +38.7%
Millennium Management 18.37K -603.52K -97.0%
Renaissance Technologies 703.59K +576.8K +454.9%
AustralianSuper Pty 158.99K -539.88K -77.3%

Financial report summary

?
Management Discussion
  • Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
  • Becton, Dickinson and Company (“BD” or the “Company”) is a global medical technology company engaged in the development, manufacture and sale of a broad range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. The Company's organizational structure is based upon three principal business segments, BD Medical (“Medical”), BD Life Sciences (“Life Sciences”) and BD Interventional (“Interventional”).
  • BD’s products are manufactured and sold worldwide. Our products are marketed in the United States and internationally through independent distribution channels and directly to end-users by BD and independent sales representatives. We organize our operations outside the United States as follows: EMEA (which includes Europe, the Middle East and Africa); Greater Asia (which includes countries in Greater China, Japan, South Asia, Southeast Asia, Korea, and Australia and New Zealand); Latin America (which includes Mexico, Central America, the Caribbean and South America); and Canada. We continue to pursue growth opportunities in emerging markets, which include the following geographic regions: Eastern Europe, the Middle East, Africa, Latin America and certain countries within Greater Asia. We are primarily focused on certain countries whose healthcare systems are expanding.
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Avg
New words: acuity, attention, bring, calendar, claimed, communicated, complex, complexity, concurrent, customary, cybersecurity, dedicated, dismissal, dispensing, documentation, empowerment, entity, equal, Euro, evidence, exhausted, final, finalization, half, high, indenture, indirect, intention, introduction, magnitude, mirrored, moved, notification, Pensionsforsikring, permanent, preliminary, pronounced, qualification, refinance, refining, refuting, rejected, requesting, responsabilit, satisfaction, spin, stage, subpoena, Superior, timeline, traditional, unanticipated, unconditionally, vacated, version
Removed: appealing, convertible, dilutive, incremental, Investor, Poor, postmarketing, reclassification, reflect, remand, sudden, WHP

Patents

GRANT
Design
Display screen with graphical user interface for an infusion device
3 Aug 21
Inventors: John Langan, Kelly Daoust, Luis Shriner, Craig Mitchell, Wendy Smyth
GRANT
Utility
Non-vented vial access syringe
3 Aug 21
A syringe includes a plunger having a plunger tube with proximal and distal ends, a center tube with a center passage that extends within the plunger tube, and a balloon disposed over the center tube and sealingly fixed to at least one of the center tube and the plunger tube.
GRANT
Utility
Intravenous tubing set modified for in-line catheter flushing
3 Aug 21
An intravenous tubing set is provided having a coupling component for accessing a source of flush solution; a flush chamber; a first IV tubing for delivering saline solution from the source of flush solution to the flush chamber; a first flow control device disposed in the tubing between the source of flush solution and the flush chamber to control the flow of flush solution into the flush chamber; a second IV tubing for delivering flush solution to a patient catheter; and a second flow control device disposed in the second tubing between the flush chamber and the patient catheter.
GRANT
Utility
Fluid line occlusion detection system and methods
3 Aug 21
The systems, methods and articles described herein are directed to at least one pressure sensor along a downstream fluid line which senses fluid pressure and assists an occlusion detection feature in determining the presence of occlusions in the downstream fluid line.
GRANT
Utility
Flow control plug securement
3 Aug 21
A catheter system may include a luer adapter, which may include an outer surface having threading or a recess.